Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
GlobeNewswire
Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia..